JPET Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomkins, D. M.
Right arrow Articles by Sellers, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomkins, D. M.
Right arrow Articles by Sellers, E. M.

Vol. 280, Issue 3, 1374-1382, 1997

Effect of Cytochrome P450 2D1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats1

D. M. Tomkins, S. V. Otton, N. Joharchi, N-Y. Li, R. F. Balster, R. F. Tyndale and E. M. Sellers

Addiction Research Foundation, 33 Russell Street, Toronto, Ontario, M5S 2S1 (D.M.T., S.V.O., N.J., N.Y.L., R.F.T., E.M.S.) and Departments of Pharmacology, Medicine and Psychiatry, University of Toronto, Toronto, Ontario, Canada (R.F.T., E.M.S.) and Center for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (R.B.)

Humans that lack cytochrome P450 2D6 (CYP2D6) activity may have an altered risk of drug dependence or abuse because this enzyme is important in the metabolism of some drugs of abuse, including hydrocodone. In rats, hydrocodone conversion to hydromorphone is catalyzed by CYP2D1, the rat homolog of the human CYP2D6. To determine the impact of impaired hydromorphone formation on the behavioral effects of the parent compound, hydrocodone-induced analgesia and hyperactivity, hydrocodone discrimination and self-administration were examined in male Wistar rats, with or without pretreatment with CYP2D1 inhibitors (quinine and budipine). In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) produced a marked suppression in brain and plasma hydromorphone levels detected after the peripheral administration of hydrocodone, thus confirming that the doses used suppressed CYP2D1 activity. In contrast, CYP2D1 inhibition had no impact on the analgesic or discriminative stimulus effects of hydrocodone, nor did this type of manipulation alter hydrocodone self-administration. The effects of quinine on the locomotor activating effects of hydrocodone were subtle at best. Because inhibition of CYP2D1 in this rat strain is proposed to be a useful animal counterpart for studying the impact of CYP2D6 polymorphism in humans, these data suggest that differences in CYP2D6 phenotype will have limited influence on the drug response to hydrocodone after nonoral administration. This has recently been verified in a study showing that inhibition of hydrocodone biotransformation to hydromorphone does not affect measures of abuse liability. Therefore, hydrocodone's behavioral effects are most likely attributable to its own intrinsic effects at mu opioid receptors.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. M. Peckham and J. R. Traynor
Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1195 - 1201.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. Lalovic, B. Phillips, L. L. Risler, W. Howald, and D. D. Shen
QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES
Drug Metab. Dispos., April 1, 2004; 32(4): 447 - 454.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley
Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Garrido, O. Sayar, C. Segura, J. Rapado, M. C. Dios-Vieitez, M. J. Renedo, and I. F. Troconiz
Pharmacokinetic/Pharmacodynamic Modeling of the Antinociceptive Effects of (+)-Tramadol in the Rat: Role of Cytochrome P450 2D Activity
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 710 - 718.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Watanabe, Y. Tarumi, D. Oneschuk, P. Lawlor, R. K. Portenoy, and R. A. Indelicato
Opioid Rotation to Methadone: Proceed With Caution
J. Clin. Oncol., May 1, 2002; 20(9): 2409 - 2410.
[Full Text] [PDF]


Home page
Br J AnaesthHome page
D. G. Williams, D. J. Hatch, and R. F. Howard
Codeine phosphate in paediatric medicine
Br. J. Anaesth., March 1, 2001; 86(3): 413 - 421.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.